Fig. 2

Lung function assessed via percent predicted forced expiratory volume in 1 s (FEV₁) at baseline and 12 months’ after omalizumab treatment, and change from baseline in percent predicted FEV₁, in patients with severe allergic asthma, with chronic rhinosinusitis with nasal polyps (CRSwNP) or without CRSwNP (No CRSwNP). The p-values within cohorts were calculated using a signed rank test and p-values for comparisons between cohorts were calculated using an ANCOVA model on ranks